Rocketing to a price of $106.75 during today's morning trading session, shares of BioNTech SE are still -23.88% below their ...

Shares of biotech companies involved in the development of monoclonal antibody cancer therapies were moving all over the ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sanofi (SNYNF – Research Report), Roche Holding AG (RHHVF – ...

Join us for a quick overview of BioNTech SE, a Biotechnology company whose shares moved 0.3% today. Here are some facts about ...

In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on BioNTech SE (BNTX – Research Report). The ...

Swiss pharmaceuticals powerhouse Roche says it plans to invest $50 billion in the United States over the next five years and ...

In its decision, the Opposition Division largely dismissed the opposition originally filed by BioNTech SE in April 2023 challenging the patent's validity and maintained the patent in amended form. The ...

In its decision, the Opposition Division largely dismissed the opposition originally filed by BioNTech SE in April 2023 challenging the patent's validity and maintained the patent in amended form.

As we previously discussed, beginning in 2022, a series of patent infringement lawsuits were filed against Moderna and collaborators Pfizer+BioNTech seeking damages based on their respective sales ...

This stipulation also does not address the litigation GSK initiated in 2024 against Pfizer, Pharmacia & Upjohn, BioNtech SE, BioNtech Manufacturing GmbH, and BioNTech US, Inc. In that case ...